REG - Cizzle Biotechnology - Result of AGM

Cizzle Biotechnology HoldingsAnnouncement

27/06/2022 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220627:nRSa3098Qa&default-theme=true

RNS Number : 3098Q  Cizzle Biotechnology Holdings PLC  27 June 2022

27 June 2022

Cizzle Biotechnology Holdings Plc

("Cizzle Biotechnology" or the "Company")

Result of AGM

Cizzle Biotechnology, the UK based diagnostics developer, announces that at
the Annual General Meeting ("AGM") of the Company held earlier today, all
resolutions were voted on by a poll and were passed.

The votes cast in respect of the resolutions were as follows:

 Resolution                                                                      For                   Against             Votes withheld
                                                                                 Total votes  %        Total votes  %
 1.   That the Annual Report and Accounts for the year ended 31 December 2021                 100.00%  0            0.00%
 be received

                                                                                 55,444,064                                30,000

 2.   For the approval of the Directors' Remuneration Policy which takes                      94.84%                0.16%
 effect immediately after the end of the AGM

                                                                                 55,297,384            90,139              86,541

 3.   For the approval of the Remuneration Report set out on pages 21 to 26                   99.84%                0.16%
 of the annual report

                                                                                 55,297,584            90,139              86,341

 4.    For the re-election of John Treacy as a director of the Company                        100.00%  0            0.00%

                                                                                 55,444,064                                30,000

 5.    For the re-election of Nigel Lee as a director of the Company                          100.00%  0            0.00%

                                                                                 55,444,064                                30,000

 6.   For the re-election of Dawn Coverley as a director of the Company                       99.94%                0.06%

                                                                                 55,409,864            34,200              30,000

 7.   For the re-appointment of PKF Littlejohn LLP as auditors to the                         100.00%  0            0.00%
 Company.

                                                                               55,444,064                                30,000

 8.   Authorises the Directors to determine the remuneration of the auditors                  99.90%                0.10%

                                                                                 55,388,125            55,939              30,000

 9.    Authorises the directors to allot shares pursuant to Section 551 of                    99.89%                0.11%
 the Companies Act 2006

                                                                                 54,796,868            58,814              618,382

 10.         Authorises the directors to allot equity securities                              94.62%                5.38%
 pursuant to Section 570 of the Companies Act 2006

                                                                                 52,358,832            2,979,293           135,939

 11.         For the approval of the adoption of the new Articles of                          100.00%  0            0.00%
 Association

                                                                                 55,444,064                                30,000

 12.         For the calling of general meetings on not less than 14                          100.00%  0            0.00%
 clear days' notice

                                                                                 55,444,064                                30,000

 

Enquiries:

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited  +44(0) 20 33285656
 John Depasquale
 Alex Brearley

 

 Novum Securities Limited  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited  +44(0) 20 3934 6630
 Tim Metcalfe          cizzle@investor-focus.co.uk
 Florence Chandler

 

Notes to Editors:

About Cizzle Biotechnology

Cizzle Biotechnology is developing a blood test for the early detection of
lung cancer.  Cizzle Biotechnology is a spin- out from the University of
York, founded in 2006 around the work of Professor Coverley and colleagues.
Its proof-of-concept prototype test is based on the ability to detect a stable
plasma biomarker, a variant of CIZ1 known as CIZ1B.  CIZ1 is a naturally
occurring cell nuclear protein involved in DNA replication, and the targeted
CIZ1B variant is highly correlated with early-stage lung cancer.

For more information, please see https://cizzlebiotechnology.com
(https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEUFSWEESELM